Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products for autoimmune and inflammatory disorders, or immuno-inflammation, with high unmet medical need. Our initial product candidate, EQ001, is a first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.